

# Isabelle Bernard-Pierrot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6686602/publications.pdf>

Version: 2024-02-01

17  
papers

1,761  
citations

687363

13  
h-index

888059

17  
g-index

21  
all docs

21  
docs citations

21  
times ranked

2463  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. <i>European Journal of Cancer</i> , 2021, 148, 181-189.	2.8	70
2	Triple extraction method enables high quality mass spectrometry-based proteomics and phospho-proteomics for eventual multi-omics integration studies. <i>Proteomics</i> , 2021, 21, 2000303.	2.2	2
3	A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. <i>Nature Communications</i> , 2021, 12, 5578.	12.8	45
4	Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives. <i>Cancers</i> , 2021, 13, 87.	3.7	10
5	Interleukin-7 receptor $\delta$ mutational activation can initiate precursor B-cell acute lymphoblastic leukemia. <i>Nature Communications</i> , 2021, 12, 7268.	12.8	24
6	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 420-433.	1.9	741
7	Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. <i>Eur Urol</i> 2019, 76:9-13. <i>European Urology</i> , 2020, 77, e26-e27.	1.9	3
8	Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. <i>Genome Medicine</i> , 2020, 12, 85.	8.2	39
9	APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. <i>European Urology</i> , 2019, 76, 9-13.	1.9	34
10	TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer. <i>British Journal of Cancer</i> , 2019, 120, 555-564.	6.4	23
11	Recurrent activating mutations of PPAR $\delta$ associated with luminal bladder tumors. <i>Nature Communications</i> , 2019, 10, 253.	12.8	44
12	An FGFR3/ MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	54
13	Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 5510-5530.	3.0	11
14	Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes. <i>Cell Reports</i> , 2014, 9, 1235-1245.	6.4	181
15	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. <i>Science Translational Medicine</i> , 2014, 6, 244ra91.	12.4	304
16	An essential role for decorin in bladder cancer invasiveness. <i>EMBO Molecular Medicine</i> , 2013, 5, 1835-1851.	6.9	45
17	Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. <i>Carcinogenesis</i> , 2006, 27, 740-747.	2.8	128